An open-label, multicenter phase II study to assess the response of subjects with metastatic breast cancer previously treated with anthracycline and taxane therapy with or without capecitabine to ZD6474 [vandetanib] (100-mg or 300-mg daily oral dose)

Trial Profile

An open-label, multicenter phase II study to assess the response of subjects with metastatic breast cancer previously treated with anthracycline and taxane therapy with or without capecitabine to ZD6474 [vandetanib] (100-mg or 300-mg daily oral dose)

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Oct 2006 Status change
    • 17 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top